Tscan Therapeutics Inc (TCRX) Cumulative Dividend Pay out History TTM by Quarter, Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 
• Dividend Growth
• Cumulative Pay out
Tscan Therapeutics Inc   (NASDAQ: TCRX)

 

TCRX's Dividend Pay out ratio over the 12 Months Period

Cumulative by Quarter, Trailing twelve months

Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.



According to the latest data Jun 30 2026, it is not possible to calculate dividend pay out ratio.
Visit Tscan Therapeutics Inc Cash flow


Dividend in Glossary



Back to TCRX Dividend Comparisons >> See also TCRX's dividend growth by quarter >> See also TCRX's eps growth
Cumulative Dividend Pay out Ratio II. Quarter
(Jun 30 2026)		 I. Quarter
(Mar 31 2026)		 IV. Quarter
(Dec 31 2025)		 III. Quarter
(Sep 30 2025)		 II. Quarter
(Jun 30 2025)
TCRX's Pay out Ratio (TTM) - - - - -
TCRX's Dividend Pay out Ratio Total Ranking # # # # #

  News about Tscan Therapeutics Inc Dividends

TScan’s High-Value Play: Premium Investment Sparks Confidence in Cancer Therapy Innovator,

TScan Therapeutics' Bold Financial Move: A 37% Premium Investment InfusionIn a striking display of investor confidence, TScan Therapeutics, Inc. (Nasdaq: TCRX) has announced a $30 million registered direct offering, marking a substantial premium above its current share values. The clinical-stage biotechnology company, renowned for its innovative T cell receptor (TCR)-engineered T cell therapy advancements, has teamed up with Lynx1 Capital Management LP and an associated investment fund, revealing a strategic partnership that holds significant implications for both the company and its investors. Key Facts from the Announcement:1. Investment Details: - TScan has entered a securities purchase agreement amounting to approximately $30 million, facilitated through the sale of pre-funded warrants. - The pre-funded warrants, equating to a total of 7,500,000 shares of voting common stock, are priced at $4.00 each. These warrants allow purchase of corresponding shares at a minuscule exercise price of $0.0001 per share. - Notably, this investment comes at a 37% premium over the last closing price of TScan's stock, and a 34% premium above the 10-day volume-weighted average closing price.

TCRX's Dividend Pay out Ratio Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
S&P 500 #

Dividend Pay out Ratio Statistics
High Average Low
0 % 0 % 0 %
 



Other Dividend Ratios
Highest Ranking Dividend Yield
Lowest Ranking Dividend Yield
Annual Dividend Pay out for TCRX
TCRX's Dividend Yield




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.